Drug Profile
Multiple sclerosis therapy - Wyeth
Alternative Names: MMS-255Latest Information Update: 19 Oct 2009
Price :
$50
*
At a glance
- Originator Wyeth
- Developer Pfizer
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Multiple sclerosis
Most Recent Events
- 15 Oct 2009 Wyeth has been acquired by Pfizer
- 16 Oct 2008 Phase-0 for Multiple sclerosis in USA (PO)